TY - JOUR AU - Uddin, Md Mokhles AU - Zabin, Meher AU - Shahnaz, Aleya AU - Akhtar, Parveen Shahida AU - Sultana, Sayeeda PY - 2009/08/20 Y2 - 2024/03/29 TI - Low Risk Group Gestational Trophoblastic Diseases - A Study of 40 Cases JF - Bangladesh Oncology Journal JA - Bang. Onc. J. VL - 4 IS - 2 SE - Original Articles DO - UR - https://www.banglajol.info/index.php/BOJ/article/view/3109 SP - 54-58 AB - <p>This prospective study was done over 40 patients suffering from low risk gestational trophoblastic diseases (GTD) from January 2002 to December 2008 in the department of Radiotherapy , Dhaka Medical College Hospital and Mitford Hospital. They aged between 18 and 45 years, mean age 26.72 years with peak occurrence (70%) in the 3rd decade (21- 30 Years). Among the 40 cases, one belonged to FIGO score- 1, eight to FIGO score-2, twenty to score-3 and 11 to score- 4. Only eight patient presented with beta-hCG above 100000u/ml.</p> <p>All the patients were planned for two weekly chemotherapy with methotrexate and leucovorin (methotrexate - 1mg/kg IV/IM on day 1,3,5,7 and oral leucovorin -0.1mg/kg on day 2,4,6,8) and were continued until beta-hCG level comes down to normal range. Then another three cycles of same chemotherapy were given. Two patients dropped during the course of chemotherapy.</p> <p>Chemotherapy schedule was changed to five drug regimen, EMA-CO schedule (etoposide-100mg/m<sup>2</sup> on day-1&amp;2, methotrexate-100mg/m<sup>2</sup> IV bolus and 200mg/m<sup>2</sup> IV drip day-1, actinomycin-D- 0.5mg/m<sup>2</sup> IV day-1&amp;2, cyclophosphamide-600mg/m<sup>2</sup> day-8 and vincristine-1mg/ m<sup>2</sup> IV day-8) due to increase in beta-hCG titre during chemotherapy with methotrexate and leucovorin. Another patient became pregnant after completion of methotrexate plus leucovorin, delivered a healthy male baby and came to us with recurrence. He was also treated with EMA-CO schedule.</p> <p>After completion of treatment, they were evaluated monthly for three months, three monthly for two years and then six monthly. Follow up period ranged between two to six years (median -four years). Among the 40 cases included in this study, two patients (5%) dropped during therapy, one (2.5%) expired due to post pregnancy recurrence and remaining 37 (92.5%) are yet in disease free state.</p> <p>(Bang. Onc. J. 2009; 4(2) : 54-58) &nbsp;&nbsp;</p> ER -